Related Experiment Video

Updated: Jun 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The effect of antidiabetic drugs on genes regulating lipid metabolism

Gerald H Tomkin1

  • 1Diabetes Institute of Ireland, Beacon Hospital, Dublin, Ireland. gerald.tomkin@tcd.ie

Current Opinion in Lipidology
|December 25, 2008
PubMed
Abstract

Insights

Antidiabetic drugs impact lipid metabolism, but evidence is limited to show they prevent cardiovascular events in diabetes. Some may even increase atherosclerosis risk due to adverse lipoprotein effects.

Area of Science:

  • Endocrinology
  • Metabolic Syndrome
  • Pharmacology

Background:

  • Hyperglycemia and dyslipidemia are closely linked in diabetes, yet cardiovascular event reduction via blood sugar control remains challenging.
  • Emerging research clarifies the complex interplay between fatty acid metabolism, insulin resistance, and cholesterol abnormalities.
  • Understanding the impact of antidiabetic medications on lipoprotein metabolism is crucial for managing diabetic complications.

Purpose of the Study:

  • To review recent literature on the effects of antidiabetic drugs on lipoprotein metabolism.
  • To explore the relationship between glucose-lowering therapies and cardiovascular risk in diabetic patients.

Main Methods:

  • Literature review of recent studies on antidiabetic drugs and their effects on lipid metabolism.
  • Analysis of genetic and molecular pathways involved in insulin resistance, diabetes, and lipoprotein abnormalities.

Main Results:

  • Postprandial lipoproteins are identified as a significant risk factor.
  • Insulin resistance and diabetes are linked to chylomicron production and clearance abnormalities.
  • Metformin's multifaceted actions and the role of PPAR-gamma in insulin sensitivity and lipoproteins are discussed.
  • Potential lipoprotein implications of GLP-1 agonists and DPP-4 inhibitors are noted, though evidence is sparse.

Conclusions:

  • Antidiabetic drugs influence lipid metabolism, but their efficacy in preventing diabetes-related atherosclerosis is not well-established.
  • Some antidiabetic medications may potentially promote atherosclerosis due to adverse effects on lipoproteins.

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...